MX363584B - Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2. - Google Patents

Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.

Info

Publication number
MX363584B
MX363584B MX2015018051A MX2015018051A MX363584B MX 363584 B MX363584 B MX 363584B MX 2015018051 A MX2015018051 A MX 2015018051A MX 2015018051 A MX2015018051 A MX 2015018051A MX 363584 B MX363584 B MX 363584B
Authority
MX
Mexico
Prior art keywords
mrna
gene expression
cancer therapy
mdm2
based gene
Prior art date
Application number
MX2015018051A
Other languages
English (en)
Other versions
MX2015018051A (es
Inventor
Nichols Gwen
Chen Gong
Dangl Markus
Geho David
Zhong Hua
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015018051A publication Critical patent/MX2015018051A/es
Publication of MX363584B publication Critical patent/MX363584B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método para predecir la sensibilidad de un paciente, con cáncer, a una terapia, comprendiendo dicho método detectar el nivel de expresión de ARNm de una firma de cuatro genes que consiste de MDM2, XPC, BBC3 y CDKN2A y utilizar dicho nivel como biomarcador para predecir la respuesta del paciente a un compuesto, en donde el compuesto es inhibidor de la interacción MDM2-p53, y en donde la respuesta es una respuesta a la terapia de cáncer en un paciente y el biomarcador se mide in vitro en una muestra o muestras del paciente.
MX2015018051A 2013-07-03 2014-07-02 Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2. MX363584B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842567P 2013-07-03 2013-07-03
US201361912781P 2013-12-06 2013-12-06
PCT/EP2014/064039 WO2015000945A1 (en) 2013-07-03 2014-07-02 Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Publications (2)

Publication Number Publication Date
MX2015018051A MX2015018051A (es) 2016-03-16
MX363584B true MX363584B (es) 2019-03-27

Family

ID=51162759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015018051A MX363584B (es) 2013-07-03 2014-07-02 Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.

Country Status (13)

Country Link
EP (1) EP3017061B1 (es)
JP (2) JP6461126B2 (es)
KR (1) KR101879926B1 (es)
CN (1) CN105378112B (es)
AU (1) AU2014286237B2 (es)
BR (1) BR112015031542A2 (es)
CA (1) CA2912547A1 (es)
HK (1) HK1215453A1 (es)
IL (1) IL242692B (es)
MX (1) MX363584B (es)
RU (1) RU2016101514A (es)
SG (1) SG11201510816SA (es)
WO (1) WO2015000945A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
JP2017508442A (ja) * 2014-01-14 2017-03-30 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
JP2017532959A (ja) * 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
EP3498712B1 (en) * 2016-08-08 2024-01-03 Jiangsu Yayo Biotechnology Co. Ltd Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US20210324478A1 (en) * 2018-07-18 2021-10-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators
KR20180093849A (ko) 2018-08-09 2018-08-22 가톨릭대학교 산학협력단 줄기세포 사멸 예측 마커 및 이의 용도
WO2020124043A1 (en) * 2018-12-13 2020-06-18 Gordon Erlinda M Methods of exploiting oncogenic drivers along the human cyclin g1 pathway for cancer gene therapy
KR20190060964A (ko) 2019-05-24 2019-06-04 가톨릭대학교 산학협력단 줄기세포 사멸 예측 마커 및 이의 용도
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
JP2023539867A (ja) * 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
RU2766739C1 (ru) * 2021-04-12 2022-03-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ прогноза эффективности терапии меланомы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248120B2 (en) * 2003-05-28 2009-04-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
KR101109437B1 (ko) 2005-12-01 2012-01-31 에프. 호프만-라 로슈 아게 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린유도체
DK2294215T3 (da) * 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
ES2398342T3 (es) 2008-09-18 2013-03-15 F. Hoffmann-La Roche Ag Pirrolidina-2-carboxamidas sustituidas
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
BR112015031542A2 (pt) 2017-07-25
JP2019059737A (ja) 2019-04-18
CN105378112B (zh) 2020-10-13
HK1215453A1 (zh) 2016-08-26
AU2014286237B2 (en) 2020-08-20
RU2016101514A3 (es) 2018-05-28
EP3017061B1 (en) 2019-01-02
AU2014286237A1 (en) 2016-01-28
JP6461126B2 (ja) 2019-01-30
CA2912547A1 (en) 2015-01-08
SG11201510816SA (en) 2016-01-28
KR20160013214A (ko) 2016-02-03
KR101879926B1 (ko) 2018-08-16
RU2016101514A (ru) 2017-08-08
CN105378112A (zh) 2016-03-02
WO2015000945A1 (en) 2015-01-08
EP3017061A1 (en) 2016-05-11
JP2016529880A (ja) 2016-09-29
IL242692B (en) 2019-12-31
MX2015018051A (es) 2016-03-16

Similar Documents

Publication Publication Date Title
MX2015018051A (es) Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2.
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
NZ601348A (en) Methods for predicting response of triple-negative breast cancer to therapy
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP3504348A4 (en) USE OF GENOMIC SIGNATURES FOR PREDICTING THE REACTIVITY OF PATIENTS WITH PROSTATE CANCER TO POSTOPERATIVE RADIOTHERAPY
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
HK1213946A1 (zh) 用於使用 對前列腺癌轉移進行診斷、預後和治療的方法
MX356866B (es) Biomarcadores p53.
EA201590773A1 (ru) Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа)
NZ630421A (en) Biomarkers predictive for clinical response for glatiramer acetate
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
EA201890598A2 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
MX2014006182A (es) Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
MX2013011334A (es) Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
WO2015093948A3 (en) Means and methods for typing a breast cancer patient and assigning therapy based on the typing
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
MX2015012842A (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
PT2473854T (pt) Sistemas e métodos para tratar, diagnosticar e prever a resposta à terapia do cancro de mama